TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens
TAK-960 是一种新型口服选择性 polo 样激酶 1 抑制剂,在多种给药方案中表现出广谱临床前抗肿瘤活性
期刊:Molecular Cancer Therapeutics
影响因子:5.3
doi:10.1158/1535-7163.MCT-11-0762
Yuichi Hikichi, Kohei Honda, Kouki Hikami, Hitoshi Miyashita, Isao Kaieda, Saomi Murai, Noriko Uchiyama, Maki Hasegawa, Tomohiro Kawamoto, Takashi Sato, Takashi Ichikawa, Sheldon Cao, Zhe Nie, Lilly Zhang, Johnny Yang, Keisuke Kuida, Erik Kupperman